Canopus BioPharma, Inc. Engages Pullan Consulting to Commence the Formation of Drug Development and Licensing Partnerships

LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that it has engaged Pullan Consulting to identify and enter into drug development and licensing partnerships with large pharmaceutical companies. Pullan Consulting is a California-based biotech business development consulting firm led by Linda Pullan, Ph.D., which has served over 20 emerging and later stage pharmaceutical companies since being established in 2006.